

# Justus G Garweg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9083445/publications.pdf>

Version: 2024-02-01

65  
papers

1,953  
citations

361045

20  
h-index

264894

42  
g-index

70  
all docs

70  
docs citations

70  
times ranked

1986  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study). <i>Diabetes Care</i> , 2010, 33, 2399-2405.	4.3	656
2	Pathophysiology of Proliferative Vitreoretinopathy in Retinal Detachment. <i>Survey of Ophthalmology</i> , 2013, 58, 321-329.	1.7	129
3	Diagnostic Approach to Ocular Toxoplasmosis. <i>Ocular Immunology and Inflammation</i> , 2011, 19, 255-261.	1.0	87
4	KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema. <i>American Journal of Ophthalmology</i> , 2022, 238, 157-172.	1.7	77
5	Reactivation of ocular toxoplasmosis during pregnancy. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2005, 112, 241-242.	1.1	70
6	Outcome indicators for vitrectomy in Terson syndrome. <i>Acta Ophthalmologica</i> , 2009, 87, 222-226.	0.6	59
7	Controversies in Ocular Toxoplasmosis. <i>Ocular Immunology and Inflammation</i> , 2011, 19, 2-9.	1.0	57
8	Long-term Outcome of Intravitreal Aflibercept Treatment for Neovascular Age-Related Macular Degeneration Using a "Treat-and-Extend" Regimen. <i>Ophthalmology Retina</i> , 2019, 3, 393-399.	1.2	50
9	Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex®) in its treatment. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2016, 254, 1257-1265.	1.0	47
10	Immunopathology in ocular toxoplasmosis: facts and clues. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2009, 104, 211-220.	0.8	45
11	Aqueous Humor and Serum Immunoblotting for Immunoglobulin Types G, A, M, and E in Cases of Human Ocular Toxoplasmosis. <i>Journal of Clinical Microbiology</i> , 2004, 42, 4593-4598.	1.8	43
12	Cytokine profiles in the aqueous humor and serum of patients with dry and treated wet age-related macular degeneration. <i>PLoS ONE</i> , 2018, 13, e0203337.	1.1	40
13	Comparison of cytokine profiles in the aqueous humor of eyes with pseudoexfoliation syndrome and glaucoma. <i>PLoS ONE</i> , 2017, 12, e0182571.	1.1	35
14	Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes. <i>Journal of Clinical Medicine</i> , 2021, 10, 2666.	1.0	34
15	Vitreous Cytokine Profile Differences Between Eyes With Epiretinal Membranes or Macular Holes. , 2016, 57, 6320.		33
16	Effects of daunorubicin, mitomycin, azathioprine and cyclosporin on human retinal pigmented epithelial, corneal endothelial and conjunctival cell lines. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2006, 244, 382-389.	1.0	30
17	Visual function in human ocular toxoplasmosis. <i>British Journal of Ophthalmology</i> , 2007, 91, 233-236.	2.1	30
18	Therapy for Ocular Toxoplasmosis "The Future. <i>Ocular Immunology and Inflammation</i> , 2013, 21, 300-305.	1.0	24

#	ARTICLE	IF	CITATIONS
19	Biomarkers for PVR in rhegmatogenous retinal detachment. <i>PLoS ONE</i> , 2019, 14, e0214674.	1.1	23
20	The fate of eyes with wet AMD beyond four years of anti-VEGF therapy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2018, 256, 823-831.	1.0	22
21	IMPACT OF INNER LIMITING MEMBRANE PEELING ON VISUAL RECOVERY AFTER VITRECTOMY FOR PRIMARY RHEGMATOGENOUS RETINAL DETACHMENT INVOLVING THE FOVEA. <i>Retina</i> , 2019, 39, 853-859.	1.0	21
22	Isoforms of TGF- $\beta$ 2 in the aqueous humor of patients with pseudoexfoliation syndrome and a possible association with the long-term stability of the capsular bag after cataract surgery. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2017, 255, 1763-1769.	1.0	20
23	Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept. <i>Ophthalmology Retina</i> , 2019, 3, 567-575.	1.2	19
24	The Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7585.	1.8	19
25	The antibody response in experimental ocular toxoplasmosis. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2006, 244, 1668-1679.	1.0	18
26	Low rate shedding of HSV-1 DNA, but not of infectious virus from human donor corneae into culture media. , 1997, 52, 320-325.		17
27	Review for Disease of the Year: Treatment of Viral Anterior Uveitis: A Perspective. <i>Ocular Immunology and Inflammation</i> , 2018, 26, 1135-1142.	1.0	17
28	Specific antibody levels in the aqueous humor and serum of two distinct populations of patients with ocular toxoplasmosis. <i>International Journal of Medical Microbiology</i> , 2005, 295, 287-295.	1.5	15
29	Cytokine profiles of phakic and pseudophakic eyes with primary retinal detachment. <i>Acta Ophthalmologica</i> , 2019, 97, e580-e588.	0.6	15
30	Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) – A meta-analysis. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2021, 259, 2181-2192.	1.0	14
31	Ocular TGF- $\beta$ 2, Matrix Metalloproteinases, and TIMP-1 Increase with the Development and Progression of Diabetic Retinopathy in Type 2 Diabetes Mellitus. <i>Mediators of Inflammation</i> , 2021, 2021, 1-10.	1.4	13
32	Treatment Strategy in Human Ocular Toxoplasmosis: Why Antibiotics Have Failed. <i>Journal of Clinical Medicine</i> , 2021, 10, 1090.	1.0	12
33	Real-Life Experience with Aflibercept and Ranibizumab in the Treatment of Newly Diagnosed Neovascular Age-Related Macular Degeneration over 24 Months. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2017, 33, 567-572.	0.6	11
34	Comparison of Strategies of Treatment with Ranibizumab in Newly-Diagnosed Cases of Neovascular Age-Related Macular Degeneration. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2017, 33, 773-778.	0.6	10
35	&lt;p&gt;Adding a Corticosteroid or Switching to Another Anti-VEGF in Insufficiently Responsive Wet Age-Related Macular Degeneration&lt;/p&gt;. <i>Clinical Ophthalmology</i> , 2019, Volume 13, 2403-2409.	0.9	10
36	Risks and Challenges in Interpreting Simultaneous Analyses of Multiple Cytokines. <i>Translational Vision Science and Technology</i> , 2020, 9, 27.	1.1	10

#	ARTICLE	IF	CITATIONS
37	Continued anti-VEGF treatment does not prevent recurrences in eyes with stable neovascular age-related macular degeneration using a treat-and-extend regimen: a retrospective case series. <i>Eye</i> , 2022, 36, 862-868.	1.1	10
38	Anti-retinal autoantibodies in experimental ocular and systemic toxoplasmosis. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 573-584.	1.0	9
39	Peripheral blood CD163(+) monocytes and soluble CD163 in dry and neovascular age-related macular degeneration. <i>FASEB Journal</i> , 2020, 34, 8001-8011.	0.2	9
40	Visual Outcome after Intravitreal Anti-VEGF Therapy for Macular Neovascularisation Secondary to Sorsby's Fundus Dystrophy: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 2433.	1.0	9
41	Pre-Existing RPE Atrophy and Defects in the External Limiting Membrane Predict Early Poor Visual Response to Ranibizumab in Neovascular Age-Related Macular Degeneration. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2017, 48, 326-332.	0.4	9
42	Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration – results from the randomized, phase IIIb OCTAVE study. <i>BMC Ophthalmology</i> , 2020, 20, 18.	0.6	8
43	HSV-1 antigens and DNA in the corneal explant buttons of patients with non-herpetic or clinically atypical herpetic stromal keratitis. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2003, 241, 734-739.	1.0	7
44	Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial. <i>Advances in Therapy</i> , 2022, 39, 2701-2716.	1.3	7
45	Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2021, 259, 3569-3578.	1.0	6
46	Local and systemic gene expression levels of IL-10, IL-17 and TGF- $\beta$ 2 in active ocular toxoplasmosis in humans. <i>Cytokine</i> , 2021, 146, 155643.	1.4	6
47	Effect of Preoperative Intraocular Pressure in Patients with and without Intolerance to Their IOP-Lowering Medication on the Outcome of Trabectome Surgery. <i>Clinical Ophthalmology</i> , 2021, Volume 15, 1851-1860.	0.9	5
48	Hybrid 23/27 Gauge Vitrectomy – Combining the Charm of 27G with the Efficacy of 23G. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 299-305.	0.9	4
49	Postoperative proliferative vitreoretinopathy development is linked to vitreal CXCL5 concentrations. <i>Scientific Reports</i> , 2021, 11, 23989.	1.6	4
50	Impact of Vitreal Tamponade on Functional Outcomes in Vitrectomy with ILM Peeling in Primary Macula-Involving Retinal Detachment: A Retrospective Analysis. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 4493-4500.	0.9	3
51	Clinical and laboratory diagnosis of ocular toxoplasmosis. <i>Expert Review of Ophthalmology</i> , 2008, 3, 333-346.	0.3	2
52	Early Response to Ranibizumab Is Predictive of Treatment Demand after a Therapeutic Switch to Aflibercept. <i>Ophthalmology Retina</i> , 2017, 1, 210-216.	1.2	2
53	Past and prognosis of anti-VEGF therapy for wet age-related macular degeneration – the future has begun. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2018, 256, 1553-1555.	1.0	2
54	Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration. <i>Clinical Ophthalmology</i> , 2019, Volume 13, 1289-1295.	0.9	2

#	ARTICLE	IF	CITATIONS
55	The double-edged role of internal limiting membrane peeling during primary rhegmatogenous retinal detachment repair. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2021, 259, 3191-3192.	1.0	2
56	Pitfalls in the Interpretation of Intraocular Inflammation in Response to Intravitreal Brolucizumab Injection. <i>Ocular Immunology and Inflammation</i> , 2021, , 1-3.	1.0	2
57	Outer retinal features in OCT predict visual recovery after primary macula-involving retinal detachment repair. <i>PLoS ONE</i> , 2022, 17, e0268028.	1.1	2
58	Long-term Efficacy of TNF-alpha Inhibitors on Persistent Uveitic Macular Edema: A Swiss Multicenter Cohort Study. <i>Ocular Immunology and Inflammation</i> , 2023, 31, 981-988.	1.0	2
59	Reply. <i>Retina</i> , 2020, 40, e8-e10.	1.0	1
60	Sulfadiazine plasma concentrations in women with pregnancy-acquired compared to ocular toxoplasmosis under pyrimethamine and sulfadiazine therapy: a caseâ€“control study. <i>European Journal of Medical Research</i> , 2020, 25, 59.	0.9	1
61	Outcome of treatment for neovascular age-related macular degeneration by practice-based ophthalmologists compared with a macula clinic. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2020, 258, 1405-1410.	1.0	1
62	Pathophysiological Considerations in Periorbital Necrotizing Fasciitis: A Case Report. <i>Ocular Immunology and Inflammation</i> , 2022, , 1-6.	1.0	1
63	Functional Outcome After Macular Hole Surgery: Comparison of Standard Perimetry with Microperimetry. <i>Clinical Ophthalmology</i> , 0, Volume 16, 2235-2243.	0.9	1
64	Impact of treatment on long-term visual function in retinal vein occlusionâ€“response to the comment on: retinal vein occlusion and the use of a dexamethasone intravitreal implant (OzurdexÂ®) in its treatment. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2016, 254, 2479-2480.	1.0	0
65	Choroidal Neovascularization Resulting from Angioid Streaks in Pseudoxanthoma Elasticum. <i>Ophthalmology Retina</i> , 2019, 3, 31.	1.2	0